In fact, it might be predicted that such inhibitors might lead to increased levels of glutamine within the tumour microenvironment, due to decreased utilisation by tumour cells, which would facilitate the expression of cMyc and anti-tumour effector functions in tumour-infiltrating NK cells. The gene discussed is MYC; the disease is neoplasm.